▲ 1.24%
prev close
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
+2
2 buys · 0 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-02-16 | TAKTakeda Pharmaceutical Company Limited American Depositary Shares | Buy | $1,001 - $15,000 | 1142d ago | — | |
| 2022-11-01 | TAKTakeda Pharmaceutical Company Limited American Depositary Shares | Buy | $1,001 - $15,000 | 1229d ago | — |
2023-02-16
Virginia Foxx
TAK
Amount
$1,001 - $15,000
Filed
1142d ago
2022-11-01
Virginia Foxx
TAK
Amount
$1,001 - $15,000
Filed
1229d ago
Recent News
Powered by Polygon.io
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight
Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Trade Timeline
Congressional activity, newest first
Virginia Foxx
2023-02-16 · Purchase
$1,001 - $15,000
Virginia Foxx
2022-11-01 · Purchase
$1,001 - $15,000